نتایج جستجو برای: 177lu dotatate

تعداد نتایج: 1456  

Journal: :Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2010
Rajaventhan Srirajaskanthan Irfan Kayani Anne Marie Quigley Jade Soh Martyn E Caplin Jamshed Bomanji

UNLABELLED (111)In-diethylenetriaminepentaacetic acid (DTPA)-octreotide scintigraphy is currently the nuclear medicine imaging modality of choice for identifying neuroendocrine tumors. However, there are cohorts of patients in whom scintigraphy findings are negative or equivocal. We evaluated the role of (68)Ga-DOTATATE PET in a selected group of patients with negative or weakly positive findin...

Journal: :Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2016
Stephen A Deppen Eric Liu Jeffrey D Blume Jeffrey Clanton Chanjuan Shi Laurie B Jones-Jackson Vipul Lakhani Richard P Baum Jordan Berlin Gary T Smith Michael Graham Martin P Sandler Dominique Delbeke Ronald C Walker

UNLABELLED Our purpose was to evaluate the safety and efficacy of (68)Ga-DOTATATE PET/CT compared with (111)In-pentetreotide imaging for diagnosis, staging, and restaging of pulmonary and gastroenteropancreatic neuroendocrine tumors. METHODS (68)Ga-DOTATATE PET/CT and (111)In-pentetreotide scans were obtained for 78 of 97 consecutively enrolled patients with known or suspected pulmonary or ga...

2012
Geetanjali Arora Jaya Shukla Sourabh Ghosh Subir Kumar Maulik Arun Malhotra Gurupad Bandopadhyaya

BACKGROUND Peptide receptor radionuclide therapy (PRRT), employed for treatment of neuroendocrine tumors (NETs) is based on over-expression of Somatostatin Receptors (SSTRs) on NETs. It is, however, limited by high uptake and retention of radiolabeled peptide in kidneys resulting in unnecessary radiation exposure thus causing nephrotoxicity. Employing a nanocarrier to deliver PRRT drugs specifi...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2014
M Lopera Sierra D Kwekkeboom M F Mariani L Bodei P Santoro E P Krenning

1165TiP Citation: Annals of Oncology, Volume 25, Supplement 4, 2014 NETTER-1: FIRST PIVOTAL PHASE III STUDY EVALUATING 177LU-DOTATATE IN MIDGUT NEUROENDOCRINE TUMOURS M. Lopera Sierra, D. Kwekkeboom, M.F. Mariani, L. Bodei, P. Santoro, E.P. Krenning 1 Medical Affaires, Advanced Accelerator Applications, Saint Genis Pouilly, FRANCE 2 Nuclear Medicine, Erasmus University Medical Center, Rotterdam...

2016
Tobias Magnander Johanna Svensson Magnus Båth Peter Gjertsson Peter Bernhardt

The aims of this study were to determine how different background regions of interest (ROIs) around the kidney represent true background activity in over- and underlying tissues in (177)Lu-DOTA-octreatate ((177)Lu-DOTATATE) treatments and to determine the influence of the background positions on the kidney activity concentration estimates by the conjugate view (ConjV) and posterior view (PostV)...

2014
Robin de Nijs Vera Lagerburg Thomas L. Klausen Søren Holm

PURPOSE Patient-specific dosimetry of lutetium-177 ((177)Lu)-DOTATATE treatment in neuroendocrine tumours is important, because uptake differs across patients. Single photon emission computer tomography (SPECT)-based dosimetry requires a conversion factor between the obtained counts and the activity, which depends on the collimator type, the utilized energy windows and the applied scatter corre...

2012
Xiang Li Samuel Samnick Constantin Lapa Ina Israel Andreas K Buck Michael C Kreissl Wolfgang Bauer

BACKGROUND Ga-[1,4,7,10-tetraazacyclododecane-N,N',N″,N'″-tetraacetic acid]-d-Phe1,Tyr3-octreotate (DOTATATE) positron emission tomography (PET) is commonly used for the visualization of somatostatin receptor (SSTR)-positive neuroendocrine tumors. SSTR is also known to be expressed on macrophages, which play a major role in inflammatory processes in the walls of coronary arteries and large vess...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید